Date: 7 April 2026

068958.0001

NovaBridge Biosciences

2440 Research Boulevard, Suite 400

Rockville, MD 20850

United States

Dear Sir or Madam

NovaBridge Biosciences (the Company)

We are attorneys-at-law qualified to practice in the Cayman Islands and have acted as Cayman Islands legal advisers to the Company in connection with the filing by the Company with the United States Securities and Exchange Commission (the SEC) of an annual report on Form 20-F for the year ended 31 December 2025 (the Form 20-F).

We hereby consent to the reference of our name under the headings “Item 3. Key Information—D. Risk Factors—General Risks Related to Our ADSs,” “Item 5. Operating and Financial Review and Prospects–Taxation–Cayman Islands” and “Item 10. Additional Information—E. Taxation—Cayman Islands” in the Form 20-F.

We consent to the filing with the SEC of this consent letter as an exhibit to the Form 20-F. In giving such consent, we do not thereby admit that we come within the category of persons whose consent is required under Section 7 of the Securities Act of 1933, or under the Securities Exchange Act of 1934, in each case, as amended, or the regulations promulgated thereunder.